OR WAIT 15 SECS
A new report from GBI Reserch available from Reportlinker.com,Â "Hospital-Acquired Bacterial Infections Market to 2017,"Â predicts that this market will decline at a negative CAGR of 3.4 percent in the forecast period of 2010 to 2017.
The global hospital-acquired bacterial infections (HABI)Â market mainly comprises of four indications which are urinary tract infections (UTIs), pneumonia, bloodstream infections (BSIs) and surgical site infections (SSIs). The total market of HABI is dependent on the major infections which are mainly caused by multidrug-resistant bacteria. Increasing human resistance to antibacterials leads to a need for advanced therapies to treat bacterial infections.
Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market, according to the report. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial R&D due to low return on investment. The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widenÂ its antibacterial pipeline portfolio.
According to the report, decline in the HABI market will be due to two main factors. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on Centers for Disease Control and Prevention (CDC) data, 20 percentÂ to 30 percentÂ of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare environment.